Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
July 26, 2023
Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new…
Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
April 6, 2023
Accelerates plans for Phase IIa study
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
February 1, 2023
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a Non-Executive Director of Infex with immediate…
Antimicrobial discovery and drug development – RSC Podcast
January 26, 2023
How do we develop drugs like antibiotics? How long does it take for such a drug to go from its inception in a research lab to use in a…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
January 5, 2023
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional five-years of market exclusivity upon approval.
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
November 21, 2022
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in…
Infex Awarded Biomedical Catalyst Grant For COV-X Project
August 8, 2022
Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18…
COVID-19 Pandemic Triggers Upsurge in MBL Infections
July 4, 2022
New research has discovered that the ongoing COVID-19 pandemic has triggered a significant upsurge in metallo-β-lactamase (MBL)……
CARB-X Receives Additional $370m from U.S. Government and Wellcome
May 25, 2022
Enables continued investment in innovative projects to tackle the growing global threat posed by AMR
Infex Therapeutics to begin clinical development of anti-virulence therapy for Pseudomonas aeruginosa (Pa) in non-cystic fibrosis bronchiectasis patients
May 16, 2022
MHRA grants approval of Phase 1 clinical trial, expected to start in H2 2022